New hope for rare amyloidosis: targeted drug combo enters trial
NCT ID NCT07335887
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This phase 2 trial tests a drug called sonrotoclax, combined with dexamethasone and sometimes daratumumab, in 39 people with a specific genetic form of AL amyloidosis (t(11;14)). The goal is to see if the treatment can quickly reduce harmful protein levels and improve organ function. Participants will receive the therapy for 12 cycles, and researchers will monitor response rates and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sonrotoclax (a targeted drug) plus dexamethasone, with or without daratumumab
- What this could lead to
- If successful, this could offer a new treatment option for people with a specific genetic type of AL amyloidosis, potentially improving organ function and survival.
- What could go wrong
- This is a small, early-phase trial with only 39 participants, so results may not apply broadly. The drug may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS (AL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, China
-
Peking University People's Hospital
RECRUITINGBeijing, China
-
The first Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITINGXi'an, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.